IN2014DN08598A - - Google Patents
Info
- Publication number
- IN2014DN08598A IN2014DN08598A IN8598DEN2014A IN2014DN08598A IN 2014DN08598 A IN2014DN08598 A IN 2014DN08598A IN 8598DEN2014 A IN8598DEN2014 A IN 8598DEN2014A IN 2014DN08598 A IN2014DN08598 A IN 2014DN08598A
- Authority
- IN
- India
- Prior art keywords
- cmax
- agent
- caverage
- ratio
- hydrophilicity
- Prior art date
Links
- 239000003814 drug Substances 0.000 abstract 2
- 229940124597 therapeutic agent Drugs 0.000 abstract 2
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 238000007920 subcutaneous administration Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/36—Blood coagulation or fibrinolysis factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/36—Blood coagulation or fibrinolysis factors
- A61K38/37—Factors VIII
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/482—Serine endopeptidases (3.4.21)
- A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Hematology (AREA)
- Zoology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dermatology (AREA)
- Diabetes (AREA)
- Inorganic Chemistry (AREA)
- Dispersion Chemistry (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Endocrinology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1206628.8A GB201206628D0 (en) | 2012-04-16 | 2012-04-16 | Subcutaneous administration of PEGylated blood clotting factors |
| GBGB1213712.1A GB201213712D0 (en) | 2012-08-01 | 2012-08-01 | Modified therapeutic agents |
| GBGB1214985.2A GB201214985D0 (en) | 2012-08-22 | 2012-08-22 | Modified therapeutic agents |
| PCT/EP2013/057928 WO2013156488A2 (en) | 2012-04-16 | 2013-04-16 | Optimised subcutaneous therapeutic agents |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2014DN08598A true IN2014DN08598A (mo) | 2015-05-22 |
Family
ID=48190923
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN8598DEN2014 IN2014DN08598A (mo) | 2012-04-16 | 2013-04-16 |
Country Status (29)
| Country | Link |
|---|---|
| US (2) | US20150086524A1 (mo) |
| EP (1) | EP2838566A2 (mo) |
| JP (3) | JP2015512927A (mo) |
| KR (1) | KR102137290B1 (mo) |
| CN (1) | CN104411335A (mo) |
| AP (1) | AP2014008049A0 (mo) |
| AU (3) | AU2013248296A1 (mo) |
| BR (1) | BR112014025737A2 (mo) |
| CA (1) | CA2869993C (mo) |
| CL (1) | CL2014002773A1 (mo) |
| CO (1) | CO7151496A2 (mo) |
| CR (1) | CR20140475A (mo) |
| EA (1) | EA033469B1 (mo) |
| EC (1) | ECSP14023048A (mo) |
| GB (3) | GB201910190D0 (mo) |
| GE (1) | GEP201706716B (mo) |
| HK (1) | HK1200695A1 (mo) |
| IL (1) | IL235129B (mo) |
| IN (1) | IN2014DN08598A (mo) |
| MD (1) | MD20140123A2 (mo) |
| MX (2) | MX2014012512A (mo) |
| MY (1) | MY190257A (mo) |
| NI (1) | NI201400122A (mo) |
| NZ (1) | NZ701205A (mo) |
| PE (1) | PE20150226A1 (mo) |
| PH (1) | PH12014502314B1 (mo) |
| SG (1) | SG11201406492YA (mo) |
| WO (1) | WO2013156488A2 (mo) |
| ZA (1) | ZA201407370B (mo) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109498815B (zh) * | 2013-12-30 | 2022-07-22 | 江苏众红生物工程创药研究院有限公司 | 重组人激肽释放酶的化学修饰物及其应用 |
| GB201417589D0 (en) | 2014-10-06 | 2014-11-19 | Cantab Biopharmaceuticals Patents Ltd | Pharmaceutical Formulations |
| FR3034669B1 (fr) * | 2015-04-07 | 2020-02-14 | Laboratoire Francais Du Fractionnement Et Des Biotechnologies | Nouvelle utilisation du facteur von willebrand |
| EP3307237A1 (en) * | 2015-06-12 | 2018-04-18 | Laboratoire Français du Fractionnement et des Biotechnologies | Injectable composition of factor vii and fillers |
| GB201518171D0 (en) | 2015-10-14 | 2015-11-25 | Cantab Biopharmaceuticals Patents Ltd | Colloidal particles for topical administration with therapeutic agent |
| GB201518170D0 (en) | 2015-10-14 | 2015-11-25 | Cantab Biopharmaceuticals Patents Ltd | Colloidal particles for subcutaneous administration with intravenous administration of therapeutic agent |
| GB201518172D0 (en) | 2015-10-14 | 2015-11-25 | Cantab Biopharmaceuticals Patents Ltd | Colloidal particles for use in medicine |
| CN109998994B (zh) * | 2018-02-13 | 2021-12-07 | 四川大学 | 包含药物的柔性脂质体及其制备方法 |
| CN114929261A (zh) | 2020-02-17 | 2022-08-19 | 生物测试股份公司 | 凝血因子viii的皮下施用 |
| WO2021216372A1 (en) * | 2020-04-23 | 2021-10-28 | Eli Lilly And Company | Subcutaneous absorption and bioavailability of antibodies |
Family Cites Families (58)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1479268A (en) | 1973-07-05 | 1977-07-13 | Beecham Group Ltd | Pharmaceutical compositions |
| US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| CH596313A5 (mo) | 1975-05-30 | 1978-03-15 | Battelle Memorial Institute | |
| US4414147A (en) | 1981-04-17 | 1983-11-08 | Massachusetts Institute Of Technology | Methods of decreasing the hydrophobicity of fibroblast and other interferons |
| US4496689A (en) | 1983-12-27 | 1985-01-29 | Miles Laboratories, Inc. | Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer |
| WO1987000056A1 (en) | 1985-06-26 | 1987-01-15 | Cetus Corporation | Solubilization of proteins for pharmaceutical compositions using polymer conjugation |
| WO1990015628A1 (en) * | 1989-06-14 | 1990-12-27 | Cetus Corporation | Polymer/antibiotic conjugate |
| WO1994005332A2 (en) | 1992-09-01 | 1994-03-17 | Berlex Laboratories, Inc. | Glycolation of glycosylated macromolecules |
| JP3866279B2 (ja) | 1992-09-28 | 2007-01-10 | リサーチ コーポレイション テクノロジーズ，インコーポレイテッド | ペプチド連結用の新規な試薬 |
| US5621039A (en) * | 1993-06-08 | 1997-04-15 | Hallahan; Terrence W. | Factor IX- polymeric conjugates |
| IL113010A (en) | 1994-03-31 | 1999-10-28 | Pharmacia & Upjohn Ab | Pharmaceutical formulation comprising factor viii with an activity of at least 500iu/ml and an enhancer for improved subcutaneous intramuscular or intradermal administration |
| JPH0892294A (ja) * | 1994-09-29 | 1996-04-09 | Teijin Ltd | ヒト活性化プロテインｃ誘導体 |
| US5693609A (en) | 1994-11-17 | 1997-12-02 | Eli Lilly And Company | Acylated insulin analogs |
| JPH08325270A (ja) * | 1995-05-31 | 1996-12-10 | Bristol Myers Squibb Co | β−ラクタマーゼに対するポリマープロドラッグおよびその使用 |
| SE9503380D0 (sv) * | 1995-09-29 | 1995-09-29 | Pharmacia Ab | Protein derivatives |
| AU5773798A (en) | 1997-01-29 | 1998-08-18 | Polymasc Pharmaceuticals Plc | Pegylation process |
| WO1999043357A1 (en) * | 1998-02-25 | 1999-09-02 | Micrologix Biotech Inc. | Indolicidin and cationic peptides conjugated with polymers |
| PL206148B1 (pl) * | 2000-02-11 | 2010-07-30 | Bayer HealthCare LLCBayer HealthCare LLC | Koniugat polipeptydowy, polipeptyd, sekwencja nukleotydowa, wektor ekspresyjny, komórka gospodarz, sposób wytwarzania koniugatu polipeptydowego, środek farmaceutyczny i zastosowanie koniugatu polipeptydowego |
| AU2001256148A1 (en) | 2000-05-03 | 2001-11-12 | Novo-Nordisk A/S | Subcutaneous administration of coagulation factor vii |
| US20030211094A1 (en) * | 2001-06-26 | 2003-11-13 | Nelsestuen Gary L. | High molecular weight derivatives of vitamin k-dependent polypeptides |
| MXPA04012496A (es) * | 2002-06-21 | 2005-09-12 | Novo Nordisk Healthcare Ag | Glicoformos del factor vii pegilados. |
| ATE503498T1 (de) * | 2002-06-21 | 2011-04-15 | Novo Nordisk Healthcare Ag | Pegylierte glykoformen von faktor vii |
| EP2572733A1 (en) * | 2003-02-26 | 2013-03-27 | Nektar Therapeutics | Polymer-factor VIII moiety conjugates |
| PL1620118T3 (pl) * | 2003-04-08 | 2014-11-28 | Yeda Res & Dev | Leki odwracalnie pegylowane |
| US20130137157A1 (en) * | 2003-04-09 | 2013-05-30 | Novo Nordisk A/S | Glycopegylated factor vii and factor viia |
| WO2006127896A2 (en) | 2005-05-25 | 2006-11-30 | Neose Technologies, Inc. | Glycopegylated factor ix |
| GB0316294D0 (en) | 2003-07-11 | 2003-08-13 | Polytherics Ltd | Conjugated biological molecules and their preparation |
| US20060198819A1 (en) | 2003-08-08 | 2006-09-07 | Novo Nordisk Healthcare A/G | Use of galactose oxidase for selective chemical conjugation of protractor molecules to proteins of therapeutic interest |
| CN100515422C (zh) | 2004-03-04 | 2009-07-22 | 卫材R&D管理有限公司 | 含有苄脒衍生物的组合物及苄脒衍生物的稳定化方法 |
| KR101100059B1 (ko) * | 2004-06-30 | 2011-12-29 | 넥타르 테라퓨틱스 | 중합체인자 ｉｘ 부분의 접합체 |
| WO2006013202A2 (en) | 2004-08-02 | 2006-02-09 | Novo Nordisk Health Care Ag | Conjugation of fvii |
| EP2360170A3 (en) | 2005-06-17 | 2012-03-28 | Novo Nordisk Health Care AG | Selective reduction and derivatization of engineered proteins comprinsing at least one non-native cysteine |
| CN102719508A (zh) * | 2005-08-19 | 2012-10-10 | 诺和诺德公司 | 糖基聚乙二醇化的因子vii和因子viia |
| CA2647314A1 (en) | 2006-03-31 | 2007-11-08 | Baxter International Inc. | Pegylated factor viii |
| US20100056428A1 (en) | 2006-09-01 | 2010-03-04 | Novo Nordisk Health Care Ag | Modified proteins |
| JP5876208B2 (ja) | 2006-12-15 | 2016-03-02 | バクスター・インターナショナル・インコーポレイテッドＢａｘｔｅｒ Ｉｎｔｅｒｎａｔｉｏｎａｌ Ｉｎｃｏｒｐ０Ｒａｔｅｄ | 延長されたｉｎｖｉｖｏ半減期を有する第ＶＩＩａ因子−（ポリ）シアル酸結合体 |
| CA2671676C (en) * | 2006-12-27 | 2014-04-22 | Baxter Healthcare Sa | Von willebrand factor-and factor viii-polymer conjugates having a releasable linkage |
| US20100143326A1 (en) | 2007-01-03 | 2010-06-10 | Novo Nordisk Healthcare A/G | SUBCUTANEOUS ADMINISTRATION OF COAGULATION FACTOR VIIa-RELATED POLYPEPTIDES |
| WO2008119815A1 (en) * | 2007-04-02 | 2008-10-09 | Novo Nordisk A/S | Subcutaneous administration of coagulation factor ix |
| BRPI0810172A2 (pt) | 2007-04-13 | 2014-10-14 | Catalyst Biosciences Inc | Polipeptídeos de fator vii modificado e seus usos |
| EP2014299A1 (en) | 2007-07-11 | 2009-01-14 | Novo Nordisk A/S | Subcutaneous administration of coagulation factor VII |
| DK2209494T3 (en) | 2007-10-09 | 2016-10-03 | Polytherics Ltd | New conjugated proteins and peptides |
| CA2702970A1 (en) | 2007-10-16 | 2009-04-23 | Pharmacyclics, Inc. | Manufacture, compositions and uses of coagulation factor viia modulator |
| RU2573587C2 (ru) | 2008-02-27 | 2016-01-20 | Ново Нордиск А/С | Конъюгированные молекулы фактора viii |
| TWI465247B (zh) | 2008-04-11 | 2014-12-21 | Catalyst Biosciences Inc | 經修飾的因子ｖｉｉ多肽和其用途 |
| CN102065887A (zh) * | 2008-04-16 | 2011-05-18 | 拜耳医药保健有限公司 | 因子ix的定点修饰 |
| KR20110016440A (ko) * | 2008-04-24 | 2011-02-17 | 셀틱 파르마 피이지 엘티디. | 연장된 반감기를 가진 제 ⅰⅹ 인자 접합체 |
| WO2009141433A1 (en) * | 2008-05-23 | 2009-11-26 | Novo Nordisk Health Care Ag | Low viscosity compositions comprising a pegylated gla-domain containing protein |
| CN102099058B (zh) | 2008-07-21 | 2014-10-22 | 宝力泰锐克斯有限公司 | 用于缀合生物分子的新试剂和方法 |
| DK2349341T3 (da) * | 2008-10-15 | 2014-01-06 | Baxter Int | Pegylering af rekombinante blodkoagulationsfaktorer i nærvær af bundne antistoffer |
| SMT201800486T1 (it) * | 2008-10-17 | 2018-11-09 | Baxalta Inc | Fattori sanguigni modificati comprendenti un grado basso di polimero solubile in acqua |
| WO2010083536A1 (en) * | 2009-01-19 | 2010-07-22 | Bayer Healthcare Llc | Protein conjugate having an endopeptidase-cleavable bioprotective moiety |
| SG178141A1 (en) * | 2009-07-27 | 2012-03-29 | Baxter Int | Blood coagulation protein conjugates |
| US20130040888A1 (en) * | 2010-02-16 | 2013-02-14 | Novo Nordisk A/S | Factor VIII Molecules With Reduced VWF Binding |
| GB201007357D0 (en) * | 2010-04-30 | 2010-06-16 | Leverton Licence Holdings Ltd | Conjugated factor VIII |
| GB201007356D0 (en) * | 2010-04-30 | 2010-06-16 | Leverton Licence Holdings Ltd | Conjugated factor VIIa |
| WO2012016131A1 (en) * | 2010-07-30 | 2012-02-02 | Baxter International Inc. | Nucleophilic catalysts for oxime linkage |
| WO2012088123A1 (en) * | 2010-12-22 | 2012-06-28 | Nektar Therapeutics | Polymer-factor vii moiety conjugates |
-
2013
- 2013-04-16 EA EA201491702A patent/EA033469B1/ru unknown
- 2013-04-16 IL IL235129A patent/IL235129B/en unknown
- 2013-04-16 WO PCT/EP2013/057928 patent/WO2013156488A2/en not_active Ceased
- 2013-04-16 MD MD20140123A patent/MD20140123A2/ro unknown
- 2013-04-16 CN CN201380027958.3A patent/CN104411335A/zh active Pending
- 2013-04-16 AP AP2014008049A patent/AP2014008049A0/xx unknown
- 2013-04-16 GE GEAP201313632A patent/GEP201706716B/en unknown
- 2013-04-16 GB GBGB1910190.6A patent/GB201910190D0/en not_active Ceased
- 2013-04-16 GB GBGB1910184.9A patent/GB201910184D0/en not_active Ceased
- 2013-04-16 SG SG11201406492YA patent/SG11201406492YA/en unknown
- 2013-04-16 JP JP2015504987A patent/JP2015512927A/ja active Pending
- 2013-04-16 GB GB1418864.3A patent/GB2516388A/en not_active Withdrawn
- 2013-04-16 MY MYPI2014002900A patent/MY190257A/en unknown
- 2013-04-16 AU AU2013248296A patent/AU2013248296A1/en not_active Abandoned
- 2013-04-16 PE PE2014001639A patent/PE20150226A1/es active IP Right Grant
- 2013-04-16 EP EP13719043.5A patent/EP2838566A2/en active Pending
- 2013-04-16 HK HK15100881.5A patent/HK1200695A1/xx unknown
- 2013-04-16 KR KR1020147031042A patent/KR102137290B1/ko active Active
- 2013-04-16 MX MX2014012512A patent/MX2014012512A/es unknown
- 2013-04-16 IN IN8598DEN2014 patent/IN2014DN08598A/en unknown
- 2013-04-16 US US14/394,437 patent/US20150086524A1/en not_active Abandoned
- 2013-04-16 CA CA2869993A patent/CA2869993C/en active Active
- 2013-04-16 BR BR112014025737A patent/BR112014025737A2/pt not_active Application Discontinuation
- 2013-04-16 NZ NZ701205A patent/NZ701205A/en not_active IP Right Cessation
-
2014
- 2014-10-10 ZA ZA2014/07370A patent/ZA201407370B/en unknown
- 2014-10-14 CR CR20140475A patent/CR20140475A/es unknown
- 2014-10-15 NI NI201400122A patent/NI201400122A/es unknown
- 2014-10-15 CL CL2014002773A patent/CL2014002773A1/es unknown
- 2014-10-15 PH PH12014502314A patent/PH12014502314B1/en unknown
- 2014-10-16 MX MX2020014208A patent/MX2020014208A/es unknown
- 2014-10-16 EC ECIEPI201423048A patent/ECSP14023048A/es unknown
- 2014-11-14 CO CO14252826A patent/CO7151496A2/es unknown
-
2017
- 2017-08-30 US US15/691,090 patent/US11351112B2/en active Active
- 2017-09-06 JP JP2017171545A patent/JP6550107B2/ja active Active
-
2018
- 2018-01-05 AU AU2018200111A patent/AU2018200111B2/en not_active Ceased
-
2019
- 2019-04-05 JP JP2019073048A patent/JP2019131593A/ja active Pending
-
2020
- 2020-02-06 AU AU2020200842A patent/AU2020200842A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2014DN08598A (mo) | ||
| PH12015500940A1 (en) | Bruton`s tyrosine kinase inhibitors | |
| PH12014501815A1 (en) | Purinone compounds as kinase inhibitors | |
| PH12015501067A1 (en) | Pyrrolopyrimidine compounds as kinase inhibitors | |
| MX2011007589A (es) | Tratamiento de un cancer usando una combinacion de bendamustine y un anticuerpo anti-cd20. | |
| NZ630805A (en) | Pharmaceutical combinations comprising a thionucleotide analog | |
| MX373851B (es) | Métodos de administración de tratamiento con pirfenidona. | |
| MY173215A (en) | Acetylcysteine compositions and methods of use thereof | |
| UA108885C2 (uk) | Композиція рисперидону для ін'єкційної депо-форми | |
| AU2016204185A1 (en) | Methods of administering beta7 integrin antagonists | |
| IN2012DN02137A (mo) | ||
| EP4360621A3 (en) | Formulations of bendamustine | |
| MX2021002633A (es) | Dispersiones solidas de bendamustina e infusion continua. | |
| MX337464B (es) | Profarmacos lipofilicos labiles al acido de los agentes quimioterapeuticos contra el cancer. | |
| BR112013001462B8 (pt) | Composições | |
| MX348418B (es) | Composicion ocular que contiene bromfenaco con biodisponibilidad incrementada. | |
| SG194753A1 (en) | Induction of il-12 using immunotherapy | |
| BR112014018426A8 (pt) | Composição e dispositivo para administração transdérmica, e, método para administrar uma progestina | |
| IN2014DN10134A (mo) | ||
| TN2014000418A1 (en) | Methods for treating cancer using pi3k inhibitor and mek inhibitor | |
| GEP20196947B (en) | Bremelanotide therapy for female sexual dysfunction | |
| UA111785C2 (uk) | Композиція для лікування бородавок та спосіб лікування бородавок | |
| UA63763U (ru) | Инъекционное средство с иммуностимулирующими и общеукрепляющими свойствами | |
| UA59175U (ru) | Способ медицинской реабилитации больных синдромом повышенной утомляемости | |
| UA58749U (ru) | Способ лечения стеатоза печени у больных туберкулезом |